Nalaganje...
What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Chronic lymphocytic leukemia (CLL), with an incidence rate between 4 and 6 cases per 100,000 persons per year, is considered the most prevalent leukemia in the western world. Chemoimmunotherapy (such as fludarabine, cyclophosphamide, and rituximab), bendamustine plus rituximab, and, more recently, n...
Shranjeno v:
| izdano v: | Cell Transplant |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7784498/ https://ncbi.nlm.nih.gov/pubmed/32907382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0963689720950209 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|